Abstracts tagged "Randomized Trial"

Abstract Number: 0573 • ACR Convergence 2025
Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Joseph F Merola¹, Alexis Ogdie², Alice B. Gottlieb³, Fabian Proft⁴, Nuala Brennan⁵, Alex Godwood⁵, Matthew R. Thomas⁵, Eva Cullen⁵, Kristian Reich⁶, Laura Coates⁷ and Laure Gossec⁸, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵MoonLake Immunotherapeutics AG, Zug, Switzerland, ⁶MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Sonelokimab (SLK) is a novel IL-17A- and IL-17F-inhibiting Nanobody designed to target difficult-to-reach sites of inflammation due to its small size and albumin-binding domain.…
Abstract Number: 0332 • ACR Convergence 2025
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Maryam Lasheen², Hadeer Hafez³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³⁶th October University, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1176 • ACR Convergence 2025
VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
Tarek Dawamne¹, Olivia Choi, MD, PhD, FAAD², Alison Tran³, Jacob Beer⁴, Katelyn Rowland², Theodore Alkousakis², Oyediran Adelakun², Elizabeth Skobelev², Sancharitha Ramji², Tony Ma⁵, Daphne Chan² and Jenna Lester⁶, ¹Texas A&M School of Engineering Medicine, Houston, TX, USA, Houston, TX, ²Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ³Lake Granbury Medical Center, Department of Dermatology, Dallas, TX, USA, Dallas, TX, ⁴Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami, FL, USA, Miami, FL, ⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁶University of California, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: Post-inflammatory pigment alteration (PIPA) following resolution of psoriasis plaques is an important, neglected problem that disproportionately impacts people of color.1-3 VISIBLE, an ongoing Phase…
Abstract Number: 0567 • ACR Convergence 2025
Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Atul Deodhar¹, Laure Gossec², Philip J. Mease³, Xenofon Baraliakos⁴, Lihi Eder⁵, Alan Kivitz⁶, Helena Marzo-Ortega⁷, Frank Behrens⁸, Ana-Maria Orbai⁹, Georg Schett¹⁰, Arthur Kavanaugh¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ⁸Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University of California, San Diego, School of Medicine, San Diego, CA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation.…
Abstract Number: 0260 • ACR Convergence 2025
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Lachelle D. Weeks¹, Danielle Hammond², Sinisa Savic³, Mael Heiblig⁴, Onima Chowdhury⁵, Arsène Mekinian⁶, Carmelo Gurnari⁷, Radhakrishanan Ramchandren⁸, Sophie georgin-Lavialle⁹, Marcela ferrada¹⁰, Sarah A. Buckley¹¹, Bryan G. harder¹¹, Sandra Goble¹¹, David Beck¹² and Matthew Koster¹³, ¹Dana Farber Cancer Institute, Boston, MA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁶Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁷Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁸University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁰University of Maryland, Bethesda, MD, ¹¹Sobi Inc., Waltham, MA, ¹²Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome is a recently identified, severe systemic hemato-inflammatory disease with a complex and heterogeneous clinical presentation. The disease is associated with significant morbidity…
Abstract Number: 1765 • ACR Convergence 2025
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
Xavier Puéchal¹, Grégory Pugnet², Elisabeth Diot³, Claire de Moreuil⁴, Stéphane Jouneau⁵, Thomas Quemeneur⁶, Gabriel Baron⁷, Perrine Smets⁸, Antoine Néel⁹, Thomas Le Gallou¹⁰, Nicolas Noël¹¹, Yurdagül Uzunhan¹², Cloé Comarmond¹³, Geoffrey Urbanski¹⁴, Ygal Benhamou¹⁵, Alice Bérezné¹⁶, Arsène Mekinian¹⁷, Mohamed Hamidou⁹, Julien Campagne¹⁸, Noemie Abisror¹⁹, Benjamin Torreau³, Pascal Cohen²⁰, Loic Guillevin²⁰, Philippe Ravaud⁷ and Benjamin Terrier²¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³Internal Medicine and Immunology, CHU Tours, Tours, France, ⁴CHU DE BREST, BREST, France, ⁵Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ⁶Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ⁷Hôtel-Dieu, Université Paris Cité,, Paris, France, ⁸Internal Medicine, CHU Gabriel-Montpied, Clermont-Ferrand, France, ⁹Internal Medicine, CHU Hôtel-Dieu, Nantes, France, ¹⁰Internal Medicine and Clinical Immunology, CHU Rennes Sud, Rennes, ¹¹Internal Medicine and Clinical Immunology, CHU Bicêtre, Bicêtre, ¹²Respiratory Medicine, Hôpital Avicenne, Bobigny, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ¹⁴Internal Medicine and Clinical Immunology, CHU Angers, Angers, France, ¹⁵Internal Medicine, CHU Rouen, Rouen, France, ¹⁶Internal Medicine, CH, Annecy, Annecy, France, ¹⁷Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁸Internal Medicine, CH Robert Schuman, Metz, France, ¹⁹Internal Medicine, CHU Saint-Antoine,, Paris, France, ²⁰Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: The eosinophilic granulomatosis with polyangiitis (EGPA) guidelines recommend considering maintenance therapy after remission to reduce the risk of relapse and toxicity, but data on…
Abstract Number: 1138 • ACR Convergence 2025
Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Robert Keenan¹, Puja Khanna², Zancong Shen³, Sarah Morris³, Pamela Mundell⁴, Wen Wei⁴, Elizabeth Polvent⁵, Vijay Hingorani⁶, Shunqi Yan⁵ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, Raleigh, NC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Arthrosi therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., San Diego, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: Pozdeutinurad (AR882, POZD) is a novel, selective URAT1 inhibitor currently in phase 3 clinical stage development for the treatment of gout and tophaceous gout.…
Abstract Number: 0558 • ACR Convergence 2025
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Julianty Angsana¹, Marta Polak¹, Sharan Nischal¹, Elizabeth Chen¹, Deepika Balakrishna², Ching-Heng Chou¹, Christopher Sisk³, Lynn Tomsho¹, Arun Kannan¹, Cynthia DeKlotz¹, Megan Miller⁴, Joseph Cafone³, Paul Newbold¹, Ya-Wen Yang¹, Monica Leung¹, Dawn Waterworth¹, Nina Sabins¹, Anna Perillo⁵, Andreas Pinter⁶ and Robert Bissonnette⁷, ¹Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ²Johnson & Johnson, San Diego, CA, USA, San Diego, USA, ³Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ⁵The Rockefeller University, New York, NY, USA, New York, NY, ⁶Goethe University Frankfurt, Frankfurt, Germany, Frankfurt, Germany, ⁷Innovaderm Research, Montreal, QC, Canada, Montreal, QC
Background/Purpose: Icotrokinra (ICO), a first-in-class targeted oral peptide that blocks the interleukin (IL)-23R and inhibits IL-23 pathway signaling, is being evaluated in the phase 3…
Abstract Number: 0826 • ACR Convergence 2025
Impact of Large Language Models on Diagnostic Reasoning of Medical Students in Rheumatology: A Randomized Trial
Anna Roemer¹, Nadine Schlicker², Anna Kernder³, Benedikt Albe¹, Juliana Hack⁴, Martin Hirsch⁵, Sebastian Kuhn¹ and Johannes Knitza⁶, ¹Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, ²Institute for Artificial Intelligence in Medicine, University Hospital Giessen and Marburg, Marburg, Germany, ³Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Center for Orthopaedics and Trauma Surgery, University Hospital Giessen and Marburg, Marburg, Germany, ⁵Institute for Artificial Intelligence in Medicine, University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany, ⁶Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany
Background/Purpose: Although not certified as medical devices, Large Language Models (LLMs) such as ChatGPT-4 provide rapid support in diagnostic reasoning and may facilitate scalable upskilling…
Abstract Number: 2671 • ACR Convergence 2025
Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
Rohit Aggarwal¹, Sebastian Rodriguez-Garcia², Agna Neto³, Despoina Papadopoulou⁴, Ben Van Baelen³, Paul Duncombe³, Leentje De Ceuninck⁵, Bas van der Woning⁶ and Hector Chinoy⁷, ¹University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ²Hospital Universitario de La Princesa, Madrid, Spain, ³argenx, Ghent, Belgium, ⁴argenx, Alimos Attikis, Greece, ⁵argenx, Issy-les-Moulineaux, France, ⁶argenx BV, Boston, MA, ⁷The University of Manchester, Manchester, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare, systemic, autoimmune, rheumatic disease, with different subtypes, characterized by muscle weakness and extra-muscular involvement. There are no…
Abstract Number: 1662 • ACR Convergence 2025
Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
Anna-Maria Hoffmann-Vold¹, Shervin Assassi², Vincent Cottin³, Michael Kreuter⁴, Claudia Valenzuela⁵, Marlies S Wijsenbeek⁶, Hui Gu⁷, Ivana Ritter⁸, Susanne Stowasser⁸, Gerrit Weimann⁸ and Toby M Maher⁹, ¹Oslo University Hospital, Oslo, Norway, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany, Heidelberg, Germany, ⁵Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain, Madrid, Spain, ⁶Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA and Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK, Los Angeles
Background/Purpose: Nerandomilast is a preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. The Phase III FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis…
Abstract Number: 0694 • ACR Convergence 2025
Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
isabelle peene¹, Gwenny Verstappen², Joke Deprez³, Frans Kroese², Suzanne Arends², Andrew Kelly⁴, Lana Vandersarren⁵, Edward Bowen⁶, Julie Jacobs⁷, Paul Meyvisch⁸, Dirk Elewaut⁹ and Hendrika Bootsma¹⁰, ¹University Hospital Ghent, Ghent, Belgium, ²University Medical Center Groningen, Groningen, Netherlands, ³Ghent University, Ghent, Belgium, ⁴Argenx, Philadelphia, PA, ⁵Argenx, Boston, MA, ⁶IQVIA, Stevenage, United Kingdom, ⁷argenx, Ravels, Belgium, ⁸argenx, Ghent, Belgium, ⁹VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹⁰UMCG, Groningen, Netherlands
Background/Purpose: Background/Purpose Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration and progressive, immune-mediated dysfunction of the exocrine glands. Immunoglobulin (Ig)…
Abstract Number: 0557 • ACR Convergence 2025
Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Lihi Eder¹, Axel Hueber², Lucia Novelli³, Tianming Gao³, Jayne Stigler⁴, Zhiyuan Du³, Rodrigo García Salinas⁵, Grace Wright⁶ and Sofia Ramiro⁷, ¹University of Toronto, Toronto, ON, Canada, ²Klinikum Nuernberg, Nuernberg, Germany, ³AbbVie, North Chicago, IL, ⁴AbbVie, Round Lake, IL, ⁵Hospital Italiano La Plata, La Plata, Argentina, ⁶Grace C Wright MD PC, New York, NY, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Biologic sex can impact both clinical phenotype and therapeutic response in PsA.1–3 Previous studies have suggested that male patients (pts) may achieve better treatment…
Abstract Number: 2663 • ACR Convergence 2025
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
David Beck¹, Mael Heiblig², Sinisa Savic³, Marcela ferrada⁴, Arsène Mekinian⁵, Onima Chowdhury⁶, Danielle Hammond⁷, Lachelle D. Weeks⁸, Carmelo Gurnari⁹, Yohei Kirino¹⁰, Sophie georgin-Lavialle¹¹, Sarah A. Buckley¹², Bryan G. harder¹², Sandra Goble¹² and Matthew Koster¹³, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ²Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ³University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁴University of Maryland, Bethesda, MD, ⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁶Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, ⁸Dana Farber Cancer Institute, Boston, MA, ⁹Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ¹⁰Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹¹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹²Sobi Inc., Waltham, MA, ¹³Mayo Clinic, Rochester, MN
Background/Purpose: VEXAS syndrome (Vacuoles, E1 ubiquitin-activating enzyme, X-linked, Autoinflammatory, Somatic) is a systemic disorder characterized by an overlap of hematologic and inflammatory features. Treatment poses…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].